Stephen A Cannistra

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
  2. ncbi request reprint Cancer of the ovary
    Stephen A Cannistra
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 351:2519-29. 2004
  3. ncbi request reprint Unique gene expression profile based on pathologic response in epithelial ovarian cancer
    Dimitrios Spentzos
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 23:7911-8. 2005
  4. pmc Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer
    Panagiotis A Konstantinopoulos
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 28:3555-61. 2010
  5. doi request reprint Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer
    Panagiotis A Konstantinopoulos
    Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 71:5081-9. 2011
  6. ncbi request reprint IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer
    Dimitrios Spentzos
    Gynecologic Medical Oncology Program, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Endocr Relat Cancer 14:781-90. 2007
  7. ncbi request reprint A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Anna Berkenblit
    Dana Farber Harvard Cancer Center Program in Gynecologic Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Gynecol Oncol 95:624-31. 2004
  8. ncbi request reprint Gene expression signature with independent prognostic significance in epithelial ovarian cancer
    Dimitrios Spentzos
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 22:4700-10. 2004
  9. doi request reprint Gene-expression profiling in epithelial ovarian cancer
    Panagiotis A Konstantinopoulos
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Nat Clin Pract Oncol 5:577-87. 2008
  10. doi request reprint Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer
    Jo Marie Tran Janco
    Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Minim Invasive Gynecol 18:629-33. 2011

Detail Information

Publications22

  1. ncbi request reprint Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
    ....
  2. ncbi request reprint Cancer of the ovary
    Stephen A Cannistra
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 351:2519-29. 2004
  3. ncbi request reprint Unique gene expression profile based on pathologic response in epithelial ovarian cancer
    Dimitrios Spentzos
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 23:7911-8. 2005
    ..We investigated whether tumor tissue obtained at diagnosis expresses a specific gene profile that is predictive of findings at second-look surgery in patients with epithelial ovarian cancer (EOC)...
  4. pmc Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer
    Panagiotis A Konstantinopoulos
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 28:3555-61. 2010
    ..To define a gene expression profile of BRCAness that correlates with chemotherapy response and outcome in epithelial ovarian cancer (EOC)...
  5. doi request reprint Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer
    Panagiotis A Konstantinopoulos
    Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 71:5081-9. 2011
    ..Our findings identify Keap1 mutations in EOC and they suggest a previously unrecognized role for the Keap1-Nrf2 pathway in mediating chemotherapeutic responses in this disease...
  6. ncbi request reprint IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer
    Dimitrios Spentzos
    Gynecologic Medical Oncology Program, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Endocr Relat Cancer 14:781-90. 2007
    ..Future studies are needed to more precisely determine the diagnostic and potential therapeutic significance of these findings...
  7. ncbi request reprint A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Anna Berkenblit
    Dana Farber Harvard Cancer Center Program in Gynecologic Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Gynecol Oncol 95:624-31. 2004
    ..To determine the activity and tolerability of weekly docetaxel in patients with platinum-resistant mullerian origin tumors...
  8. ncbi request reprint Gene expression signature with independent prognostic significance in epithelial ovarian cancer
    Dimitrios Spentzos
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 22:4700-10. 2004
    ..In this study, we investigated whether tumor transcription profiling could be used as a prognostic tool in this disease...
  9. doi request reprint Gene-expression profiling in epithelial ovarian cancer
    Panagiotis A Konstantinopoulos
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Nat Clin Pract Oncol 5:577-87. 2008
    ..In this Review, we summarize the contributions of gene-expression profiling to the diagnosis and management of epithelial ovarian cancer and discuss ways in which this technique could become a useful tool in clinical management...
  10. doi request reprint Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer
    Jo Marie Tran Janco
    Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Minim Invasive Gynecol 18:629-33. 2011
    ..To evaluate complications of intraperitoneal ports placed laparoscopically as a separate procedure after initial debulking surgery for ovarian, fallopian tube, or primary peritoneal cancer...
  11. pmc Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer
    Panagiotis A Konstantinopoulos
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e18202. 2011
    ..Public data integration may help overcome challenges in clinical implementation of microarray profiles. We integrated several ovarian cancer datasets to identify a reproducible predictor of survival...
  12. ncbi request reprint Advances in the management of epithelial ovarian cancer
    Anna Berkenblit
    Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Reprod Med 50:426-38. 2005
    ....
  13. pmc Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
    J Clin Oncol 27:5601-6. 2009
    ..Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit...
  14. ncbi request reprint The ethics of early stopping rules: who is protecting whom?
    Stephen A Cannistra
    Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Clin Oncol 22:1542-5. 2004
  15. ncbi request reprint Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin
    Anna Berkenblit
    Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gynecol Oncol 89:486-93. 2003
    ..The aim of this study was to assess the feasibility of combining docetaxel, carboplatin, and gemcitabine (DoCaGem) as first-line treatment of ovarian and other müllerian origin tumors...
  16. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  17. ncbi request reprint Granulosa cell tumor of the ovary
    Susan Tinsley Schumer
    Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 21:1180-9. 2003
    ..Because of the propensity of GCT to recur years after initial diagnosis, prolonged surveillance with serial physical examination and serum tumor markers such as estradiol and inhibin is reasonable...
  18. ncbi request reprint BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease
    Stephen A Cannistra
    Clin Cancer Res 13:7225-7. 2007
  19. doi request reprint Challenges and pitfalls of combining targeted agents in phase I studies
    Stephen A Cannistra
    J Clin Oncol 26:3665-7. 2008
  20. ncbi request reprint Intraperitoneal chemotherapy comes of age
    Stephen A Cannistra
    N Engl J Med 354:77-9. 2006
  21. ncbi request reprint Gynecologic oncology or medical oncology: what's in a name?
    Stephen A Cannistra
    J Clin Oncol 25:1157-9. 2007
  22. ncbi request reprint Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?
    Stephen A Cannistra
    J Clin Oncol 20:1158-60. 2002